Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) (the
"Company") today announced that Wanbang Biopharmaceuticals has completed two
pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies
independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and
improved Oral Glucose Tolerance in normal SD rats. The results were consistent
with those previously completed by Sirona Biochem. 


The next steps in the validation of SBM-TFC-039 will be the Pharmacokinetic
study and the 14 day toxicology repeated administration on normal SD rats. If
further positive results are obtained, as expected, Wanbang will have completed
the first milestone of its license agreement with Sirona Biochem. This will
trigger a second payment to Sirona from Wanbang Biopharmaceuticals, part of the
$9.5M in upfront and milestone payments. 


According to a 2013 study* published in The Journal of the American Medical
Association the People's Republic of China now has the greatest prevalence of
diabetes. It is estimated that 11.6% of the adult population or 114 million
people are affected; this is the first time that a country has surpassed the
United States, which has an estimated 11.3% living with the disease. 


It is also estimated that approximately half of all Chinese adults, a total of
493 million people, could be suffering from pre-diabetes, a preliminary stage in
which the sugar metabolism is already disturbed, but diabetes is not yet
present. 


"Wanbang Biopharmaceuticals dedication to quickly advancing this project to
clinical trials confirms the strength of Sirona's partnership with China's top
ranked diabetes pharmaceutical company. The value of this pharmaceutical to
Sirona grows both within China, home of the world's largest Diabetic population
and outside China to other potential pharmaceutical partners," said Howard
Verrico, Chief Executive Officer of Sirona Biochem.


* http://jama.jamanetwork.com/article.aspx?articleid=1734701

About Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is a leading pharmaceutical company in the People's
Republic of China that specializes in research, production and marketing of
medicines for diabetes, cardiovascular disease and endocrinology. Among domestic
pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest
manufacturers and marketers of a comprehensive portfolio of drugs for diabetes. 



Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group
which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major
shareholders of Sinopharm Group, the largest drug distributor in China, is part
of Fosun International, the leading non-state owned enterprise group in China
which is listed on the Hong Kong Stock Exchange.


About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a
proprietary technology platform developed at its laboratory facility in France.
The company specializes in the stabilization of carbohydrate molecules, with the
goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are
patented as new chemical entities for maximum commercial protection and revenue
potential. Newly developed compounds are licensed to leading companies around
the world in return for licensing and milestone fees and ongoing royalty
payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient
of multiple French national scientific awards and a European Union and French
government grant. For more information visit www.sironabiochem.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 


Sirona Biochem cautions you that statements included in this press release that
are not a description of historical facts may be forward-looking statements.
Forward-looking statements are only predictions based upon current expectations
and involve known and unknown risks and uncertainties. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of release of the relevant information, unless explicitly stated
otherwise. Actual results, performance or achievement could differ materially
from those expressed in, or implied by, Sirona Biochem's forward-looking
statements due to the risks and uncertainties inherent in Sirona Biochem's
business including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in development, testing,
obtaining regulatory approval, producing and marketing its products; unexpected
adverse side effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from other
pharmaceutical or biotechnology companies; and its ability to obtain additional
financing to support its operations. Sirona Biochem does not assume any
obligation to update any forward-looking statements except as required by law.



FOR FURTHER INFORMATION PLEASE CONTACT: 

For more information regarding this press release, contact:

Christopher Hopton
CFO
Sirona Biochem Corp. 
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sirona Biochem Charts.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sirona Biochem Charts.